Gilead Sciences Inc. (GILD - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion in favor of the approval of the company’s marketing authorization application for Epclusa.
Gilead is looking to get Epclusa approved for the treatment of adults with all genotypes (1-6) of chronic hepatitis C virus (HCV) infection. Epclusa is an experimental pan-genotypic, once-daily combination of Gilead’s HCV drug Sovaldi (400 mg) and velpatasvir (a pan-genotypic NS5A inhibitor; 100 mg).
The favorable opinion of the CHMP, which was adopted following an accelerated review procedure, will now be reviewed by the European Commission. With the CHMP issuing a positive opinion, we believe that chances of Epclusa gaining EU approval are pretty high.
We remind investors that Epclusa is currently under priority review in the U.S. for the same indication. A response from the FDA is expected by Jun 28.
Epclusa could become the first pan-genotypic, all-oral, single-tablet regimen to gain approval and will complement the company’s current HCV portfolio consisting of Sovaldi and Harvoni. Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor – Merck & Co. Inc.’s (MRK - Free Report) Zepatier.
Meanwhile, Gilead is also evaluating a once-daily fixed-dose combination of Sovaldi/velpatasvir plus GS-9857 (an experimental NS3 protease inhibitor) in phase III studies, for the treatment of chronic genotype 1-6 HCV.
Gilead is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Gilead Sciences Inc. (GILD - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion in favor of the approval of the company’s marketing authorization application for Epclusa.
Gilead is looking to get Epclusa approved for the treatment of adults with all genotypes (1-6) of chronic hepatitis C virus (HCV) infection. Epclusa is an experimental pan-genotypic, once-daily combination of Gilead’s HCV drug Sovaldi (400 mg) and velpatasvir (a pan-genotypic NS5A inhibitor; 100 mg).
The favorable opinion of the CHMP, which was adopted following an accelerated review procedure, will now be reviewed by the European Commission. With the CHMP issuing a positive opinion, we believe that chances of Epclusa gaining EU approval are pretty high.
We remind investors that Epclusa is currently under priority review in the U.S. for the same indication. A response from the FDA is expected by Jun 28.
Epclusa could become the first pan-genotypic, all-oral, single-tablet regimen to gain approval and will complement the company’s current HCV portfolio consisting of Sovaldi and Harvoni. Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor – Merck & Co. Inc.’s (MRK - Free Report) Zepatier.
Meanwhile, Gilead is also evaluating a once-daily fixed-dose combination of Sovaldi/velpatasvir plus GS-9857 (an experimental NS3 protease inhibitor) in phase III studies, for the treatment of chronic genotype 1-6 HCV.
Gilead is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MRK - FREE
Get the latest research report on GILD - FREE
Get the latest research report on ANIP - FREE